Welcome to our dedicated page for Envista Holdings Corporation news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings Corporation stock.
Envista Holdings Corporation (NYSE: NVST) is a leading global dental products company committed to empowering dental professionals worldwide. Headquartered in Brea, California, Envista develops, manufactures, and markets an extensive portfolio of dental consumables, equipment, and services. The company operates through two primary segments: Specialty Products & Technologies and Equipment & Consumables.
The Specialty Products & Technologies segment focuses on dental implant systems, regenerative solutions, dental prosthetics, orthodontic systems, and lab products. This segment is dedicated to advancing the capabilities of dental professionals through innovative products and technologies.
The Equipment & Consumables segment offers a broad range of dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization and magnification systems, supporting the diagnostic, treatment, and prevention needs of dental conditions.
Envista has a strong commitment to continuous improvement, action-oriented innovation, and a deep respect for dental professionals. Its comprehensive product portfolio covers an estimated 90% of dentists’ clinical needs, ensuring a holistic approach to dental care.
Recent achievements include the launch of the DEXIS digital ecosystem, an AI-powered platform designed to streamline implant dentistry workflows. This interconnected system combines cutting-edge CBCT, intraoral scanning, diagnostics, and treatment planning, empowering clinicians to manage implant cases efficiently.
Envista continues to innovate with products like the ORTHOPANTOMOGRAPH™ OP 3D™ LX, which enhances 3D diagnostic capabilities, and the IS ScanFlow software, which integrates AI-driven tools to maximize productivity in dental practices.
Financially, Envista reported sales of $623.6 million for the first quarter of 2024, with core sales growth and ongoing investments aimed at accelerating growth and profitability. The company has a proven track record of resilience and strategic differentiation, particularly through the challenges posed by the global pandemic and other economic factors.
Envista's philanthropic arm, the Envista Smile Project, exemplifies its commitment to social responsibility. The project has donated millions to improve access to oral health for underserved communities, partnering with institutions like the University of Southern California to enhance dental care for vulnerable populations.
Envista's significant market positions in attractive dental segments, coupled with its continuous improvement culture and innovation-driven approach, make it a pivotal player in the dental industry. For more information, visit the official website at www.envistaco.com.
Envista Holdings (NYSE: NVST) reported Q3 2024 financial results with sales of $601.0 million, showing a core sales decline of 5.3% compared to Q3 2023. Net income decreased to $8.2 million ($0.05 per diluted share) from $21.5 million ($0.12 per diluted share) in Q3 2023. Adjusted net income fell to $21.1 million ($0.12 per diluted share) from $75.5 million ($0.43 per diluted share). Adjusted EBITDA decreased to $54.9 million from $123.5 million year-over-year. The company maintains its full-year 2024 guidance of -1% to -4% core sales growth and adjusted EBITDA margins between 10-12%.
Envista Holdings (NYSE: NVST) has announced its upcoming third quarter 2024 earnings call, scheduled for Wednesday, October 30, 2024. The company will report its financial results and host a conference call beginning at 2:00 PM PT, expected to last about an hour.
Investors can access the call and accompanying slide presentation through a webcast on Envista's website in the "Investors" section. A replay will be available shortly after and remain accessible for one year. For those preferring to dial in, the call can be accessed at 800-225-9448 within the U.S. or +1 203-518-9708 internationally, using conference ID #6240897.
Envista will post its earnings press release, webcast slides, and related presentation materials on the company website's "Investors" section prior to the conference call.
DEXIS has announced three new innovations to enhance its digital ecosystem for dental workflows. These include:
- A new X-ray platform, ORTHOPANTOMOGRAPH™ OP 3D™ EX, designed for general practitioners to expand 3D imaging capabilities
- An update to DTX Studio™ Clinic software, enabling faster implant treatment planning and surgical guide generation
- An intraoral scanning software update featuring Oral Compare for visualizing dental issues over time and integration with SmileFy for treatment outcome simulation
These upgrades aim to streamline the implant workflow, provide deeper patient insights, and offer flexible, intuitive solutions for dental professionals.
Envista Holdings (NYSE: NVST) has announced its participation in the Baird 2024 Global Healthcare Conference. The event is scheduled for Wednesday, September 11, 2024, from 10:50 AM to 11:20 AM ET at the InterContinental New York Barclay. Envista's presence at this prominent healthcare conference suggests an opportunity for the company to showcase its developments and engage with industry professionals. However, it's worth noting that no recording link will be available for this event, limiting access to the presentation for those unable to attend in person.
Envista Holdings (NYSE: NVST) reported Q2 2024 results with sales of $633.1 million and a core sales decline of 3.2% compared to Q2 2023. The company posted a net loss of $1,151.6 million ($6.69 per share), including a $1,153.8 million non-cash charge for goodwill and intangible asset impairment. Adjusted net income was $18.5 million ($0.11 per diluted share), down from $76.2 million ($0.43 per diluted share) in Q2 2023. Adjusted EBITDA decreased to $63.0 million from $126.2 million year-over-year.
CEO Paul Keel acknowledged underperformance and outlined steps to reposition the company, including new leadership hires and growth investments. For full-year 2024, Envista expects core sales to decline 1-4% and adjusted EBITDA margins of 10-12%, with further decline in Q3 before returning to growth in Q4.
Envista Holdings (NYSE: NVST) has announced three key leadership appointments, effective in July and August 2024. Eric Hammes joins as Chief Financial Officer, bringing over 25 years of operational and financial leadership experience from Rockwell Automation and 3M. Stefan Nilsson becomes President of Nobel Biocare, with a background as CEO of Colosseum Dental Group and GrandVision Brazil. Veronica Acurio is appointed President of Orthodontics, joining from Solventum with extensive experience in global healthcare businesses, including leadership roles at 3M.
These appointments aim to strengthen Envista's position in dental implants, orthodontics, and overall financial performance. CEO Paul Keel expressed confidence that these leaders will help accelerate growth, expand margins, and advance the company's portfolio in the dental industry.
Envista Holdings (NYSE: NVST) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. The company has scheduled a conference call for the same day at 2:00 PM PT to discuss these results. The call will include a slide presentation and will be available via webcast on the 'Investors' section of Envista's website. A replay of the webcast will be accessible shortly after the call and will be available for one year. To join the call, dial 800-579-2543 (U.S.) or +1 785-424-1789 (international) and refer to conference ID #9467851. Presentation materials will be available on the company's website before the call.
Envista Holdings (NYSE: NVST) and its charitable branch, the Envista Smile Project, announced a $2.1 million donation to the University of Southern California's (USC) Herman Ostrow School of Dentistry.
This donation aims to support the Dental Health Equity and Access to Care Initiative, focusing on underserved communities, particularly children with special needs in California. The three-year donation will provide essential oral health equipment, products, and technology updates. It will also expand the USC Pediatric Clinic and Mobile Clinic, enhancing services for special needs patients, telehealth, and general care for vulnerable populations.
This partnership includes other philanthropic endeavors, like medical mission trips staffed by USC students and faculty, to bring oral care to international communities in need.
Envista Holdings (NYSE: NVST) announced its participation in the Stifel Jaws & Paws Conference, scheduled for May 29, 2024. The event will include a Fireside Chat from 4:10 to 4:40 pm ET. An audio-only recording of the session will be available on the company's Investor Relations website for up to 365 days after the event.
Envista Holdings (NYSE: NVST) reported sales of $623.6 million for the first quarter of 2024, with a 0.4% increase in core sales compared to 2023. Net income was $23.6 million, adjusted net income $45.8 million, and adjusted EBITDA $87.2 million. The company appointed Paul Keel as the new CEO. Envista remains focused on growth and profitability with a strong outlook for the future.
FAQ
What is the current stock price of Envista Holdings Corporation (NVST)?
What is the market cap of Envista Holdings Corporation (NVST)?
What does Envista Holdings Corporation do?
What are the main segments of Envista's business?
What recent achievements has Envista made?
How did Envista perform financially in the first quarter of 2024?
What is the Envista Smile Project?
Who is the new CEO of Envista Holdings Corporation?
How does Envista support dental professionals?
What is the DEXIS digital ecosystem?
What is the Envista Business System (EBS)?
Where can I find more information about Envista Holdings Corporation?
